XiaoPei Yan1, Feng Zong2, Hui Kong3, YanLi Wang3, XinYun Zhao3, WenRui Liu3, ZaiLiang Wang3, WeiPing Xie4. 1. Department of Respirology, First People's Hospital of Changzhou, Changzhou, 213000, China. 2. Department of Geriatrics, First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. 3. Department of Respirology, First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, 210029, China. 4. Department of Respirology, First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, 210029, China. wpxie@njmu.edu.cn.
Abstract
BACKGROUND: Pulmonary fungal disease is an emerging issue in immunocompetent patients, for whom the characteristics are only partially understood. METHODS: We conducted a single-center retrospective study of histologically verified pulmonary fungal disease in Eastern China from 2006 to 2014 to understand the demographics, clinical manifestations, therapeutic approaches, and factors associated with prognosis in this population. All cases were diagnosed according to the 2008 European Organization for the Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infection Diseases Mycoses Study Group definition criteria. RESULTS: A total of 112 cases of pulmonary fungal diseases were enrolled (35 proven, 16 probable, 61 possible), and we analyzed the 35 patients with histologically proven pulmonary fungal diseases in this study. The main fungal species identified were Aspergillus (51.4 %), Cryptococcus (22.9 %), and Mucor (2.4 %). Treatment consisted of antifungal therapeutic agents (54.3 %), surgery and postsurgical agents (25.7 %), or surgery alone (14.3 %). The overall crude mortality rate was 14.3 %, and the mortality due to pulmonary fungal infections was 2.9 %. Significant predictors of mortality by univariate analysis were hypoalbuminemia (P = 0.005), cancer (P = 0.008), and positive culture (P = 0.044). Additionally, hypoalbuminemia was the only risk factor for mortality by multivariate analysis (RR = 7.56, 95 % CI 1.38-41.46). CONCLUSION: Pulmonary fungal disease in immunocompetent patients, with Aspergillus as the most common identified species, had a prognosis that was influenced by the level of serum albumin.
BACKGROUND:Pulmonary fungal disease is an emerging issue in immunocompetent patients, for whom the characteristics are only partially understood. METHODS: We conducted a single-center retrospective study of histologically verified pulmonary fungal disease in Eastern China from 2006 to 2014 to understand the demographics, clinical manifestations, therapeutic approaches, and factors associated with prognosis in this population. All cases were diagnosed according to the 2008 European Organization for the Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infection Diseases Mycoses Study Group definition criteria. RESULTS: A total of 112 cases of pulmonary fungal diseases were enrolled (35 proven, 16 probable, 61 possible), and we analyzed the 35 patients with histologically proven pulmonary fungal diseases in this study. The main fungal species identified were Aspergillus (51.4 %), Cryptococcus (22.9 %), and Mucor (2.4 %). Treatment consisted of antifungal therapeutic agents (54.3 %), surgery and postsurgical agents (25.7 %), or surgery alone (14.3 %). The overall crude mortality rate was 14.3 %, and the mortality due to pulmonary fungal infections was 2.9 %. Significant predictors of mortality by univariate analysis were hypoalbuminemia (P = 0.005), cancer (P = 0.008), and positive culture (P = 0.044). Additionally, hypoalbuminemia was the only risk factor for mortality by multivariate analysis (RR = 7.56, 95 % CI 1.38-41.46). CONCLUSION:Pulmonary fungal disease in immunocompetent patients, with Aspergillus as the most common identified species, had a prognosis that was influenced by the level of serum albumin.
Authors: P G Pappas; J R Perfect; G A Cloud; R A Larsen; G A Pankey; D J Lancaster; H Henderson; C A Kauffman; D W Haas; M Saccente; R J Hamill; M S Holloway; R M Warren; W E Dismukes Journal: Clin Infect Dis Date: 2001-07-26 Impact factor: 9.079
Authors: A Cornillet; C Camus; S Nimubona; V Gandemer; P Tattevin; C Belleguic; S Chevrier; C Meunier; C Lebert; M Aupée; S Caulet-Maugendre; M Faucheux; B Lelong; E Leray; C Guiguen; J-P Gangneux Journal: Clin Infect Dis Date: 2006-07-27 Impact factor: 9.079
Authors: Thomas J Walsh; Hedy Teppler; Gerald R Donowitz; Johan A Maertens; Lindsey R Baden; Anna Dmoszynska; Oliver A Cornely; Michael R Bourque; Robert J Lupinacci; Carole A Sable; Ben E dePauw Journal: N Engl J Med Date: 2004-09-30 Impact factor: 91.245
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: William Mundo; Amber Berning; Yiannis Koullias; Daniel B Chastain; Neil Stone; Carlos Franco-Paredes; Andrés F Henao-Martínez; Lilian Vargas Barahona Journal: Open Forum Infect Dis Date: 2021-05-19 Impact factor: 3.835